Trials / Completed
CompletedNCT00978198
Safety, Tolerability and Pharmacokinetic Study of ASP1517 in Healthy Non-elderly Male Volunteers
ASP1517 Phase 1 Clinical Study - Single and Multiple Oral Dosing of ASP1517 in Healthy Non-elderly Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- Male
- Age
- 20 Years – 44 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the safety and tolerability of ASP1517 after single or multiple oral administration in healthy non-elderly adult male subjects.
Detailed description
The study consists of two parts, single and multiple dose. Within each part participants will be randomized to either ASP1517 or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASP1517 | oral |
| DRUG | Placebo | oral |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2009-09-16
- Last updated
- 2010-06-22
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00978198. Inclusion in this directory is not an endorsement.